Published in Obesity and Diabetes Week, June 27th, 2005
The first presentation, titled "BENICAR Efficacy in Systolic Hypertension Trial (BEST)," demonstrated that a BENICAR based treatment algorithm significantly reduced mean systolic blood pressure in a stage 2 systolic hypertensive population.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week